Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Random

Display 15 Products per page

Delafloxacin
Read More
Delafloxacin is a novel broad-spectrum fluoroquinolone that prevents bacterial DNA synthesis through its equal inhibitory effect against the enzymes topoisomerase II (DNA gyrase) and IV.
September 10, 2014
Find out more
Cubicin
Read More
Cubicin is a cyclic lipopeptide antibacterial that has a unique mechanism of action. It causes rapid depolarization of the bacterial cell membrane potential upon binding to the membrane.
September 10, 2014
Find out more
ABBV-066
Read More
ABBV-066 (risankizumab; AbbVie/Boehringer Ingelheim) is a humanized anti-interleukin(IL)-23 subunit p19 monoclonal antibody that binds and neutralizes the p19 subunit of IL-23.
August 26, 2016
Find out more
Actemra
Read More
Actemra (tocilizumab; Roche/Chugai), known as RoActemra in Europe, is a first-in-class humanized interleukin-6 receptor monoclonal antibody.
March 24, 2015
Find out more
ND0612
Read More
The ND0612 (Mitsubishi Tanabe) product line comprises two subcutaneous, continuously delivered carbidopa/levodopa liquid formulations: the lower-dose ND0612L, and the higher-dose ND0612H.
June 21, 2018
Find out more
Fycompa
Read More
Fycompa (perampanel; Eisai) is a selective, non-competitive, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist that exhibits antiseizure activity by reducing glutamatergic signaling.
May 23, 2017
Find out more
Ponesimod
Read More
Ponesimod is a selective sphingosine-1-phosphate (S1P)1 receptor agonist being developed by Johnson & Johnson specifically as a drug for relapsing-remitting multiple sclerosis (RRMS).
November 24, 2017
Find out more
Repatha
Read More
Repatha (evolocumab; Amgen/Astellas) is a fully human monoclonal immunoglobulin G2 antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).
November 20, 2019
Find out more
Neratinib
Read More
Neratinib (Puma Biotechnology) is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the human epidermal growth factor receptor (HER)1, HER2, HER4, and epidermal growth factor receptor kinases.
March 9, 2015
Find out more
lefitolimod
Read More
Lefitolimod is a synthetic DNA-based immunomodulator that acts as a Toll-like receptor (TLR)9 agonist.
December 11, 2017
Find out more
Viekira Pak franchise
Read More
AbbVie’s Viekira Pak franchise comprises Viekira Pak ([paritaprevir + ritonavir + ombitasvir] + dasabuvir), Viekira XR ([paritaprevir + ritonavir + ombitasvir + dasabuvir]), and Technivie ([paritaprevir + ritonavir + ombitasvir]), which is branded as Viekirax outside the US market.
November 6, 2017
Find out more
Multikine
Read More
Multikine is an investigational immunomodulator composed of a proprietary cocktail of naturally occurring cytokines such as interleukins, interferons, chemokines, and colony-stimulating factors.
December 1, 2017
Find out more
Mircera
Read More
Mircera is an ESA administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in CKD
January 11, 2018
Find out more
Toujeo
Read More
Toujeo (insulin glargine U300) is a long-acting basal insulin analog based on Sanofi’s hugely successful Lantus (insulin glargine) for use in the treatment of type 1 and type 2 diabetes. The new product is a formulation which is three times more concentrated than the original, with a reduced volume and surface area of the subcutaneous depot.
November 7, 2017
Find out more
Tezacaftor/Ivacaftor
Read More
Vertex’s tezacaftor (formerly known as VX-661) is a CFTR corrector compound being investigated as an adjunct to Vertex’s other marketed and developmental CFTR-targeting products. The drug’s initial development is as part of a fixed-dose combination with the CFTR potentiator ivacaftor (Vertex), which was approved with the brand name Kalydeco in January 2012.
September 14, 2017
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *